Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2024-04-30 Regulatory Filings
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements, 2015. It informs about the receipt of a rectification order from the Income Tax Department deleting a tax demand for Assessment Year 2015-16. The document includes an annexure detailing the litigation and relief amount. The content is an update or announcement regarding a regulatory or legal matter, specifically a tax litigation outcome, rather than a full financial report or audit. The document length is short (2597 characters) and it serves as an intimation or disclosure rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-04-30 English
Updates
Regulatory Filings Classification · 95% confidence The document is a communication addressed to stock exchanges (BSE and NSE) pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It announces the completion of a USFDA audit of a manufacturing facility and mentions that the company will submit an action plan on the observations. The document is a regulatory announcement about an event (USFDA audit completion) rather than a detailed financial report or audit report. It does not contain financial statements, management discussion, or detailed audit results. The document length is 5635 characters, which is relatively short and consistent with an announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-04-24 English
Updates
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the closure of manufacturing operations of a subsidiary's facility. It provides details about the operational change, expected cessation date, and business impact. The document is an official announcement to stock exchanges about a significant operational event, not a financial report or detailed management discussion. It does not contain financial statements or detailed financial analysis. The length is 4077 characters, which is relatively short and consistent with a regulatory announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-04-17 English
Updates
Regulatory Filings Classification · 95% confidence The document is a communication from Jubilant Pharmova Limited to stock exchanges in India, referencing a recent communication received from the USFDA regarding an inspection classification of a manufacturing facility. The document is dated April 17, 2024, and is addressed to regulatory bodies (BSE and NSE). It provides a summary of the USFDA inspection outcome, stating the classification as 'Voluntary Action Indicated (VAI)' and that the inspection is closed. The document includes company background information and contact details for investors and media. There are no financial statements, detailed financial analysis, or comprehensive report content. The document is relatively short (5938 characters) and serves as an announcement of a regulatory update rather than a full report or detailed filing. It does not contain quarterly or annual financial data, nor is it a transcript, proxy, or remuneration report. It is a regulatory announcement about compliance status from a regulatory agency. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-04-17 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document is a declaration under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, stating that the promoters and persons acting in concert have not made any encumbrance on the shares during the financial year ended March 31, 2024. It is a regulatory compliance declaration related to shareholding and encumbrance status, not a financial report, audit, or management information. It fits the category of Major Shareholding Notification or related disclosures under SEBI regulations. Given the content and regulatory reference, the best fitting category is Major Shareholding Notification (MRQ). The document is short and specific to shareholding status, not a report or announcement of a report.
2024-04-12 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the cancellation and dematerialization of physical share certificates for the quarter ended March 31, 2024. It is a compliance certificate related to share transfer and dematerialization, not a financial report or announcement of financial results. The document is short (2899 characters) and serves as a regulatory compliance filing rather than a report or announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2024-04-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.